These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 15173014)

  • 41. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.
    De Giovanni C; Nicoletti G; Palladini A; Croci S; Landuzzi L; Antognoli A; Murgo A; Astolfi A; Ferrini S; Fabbi M; Orengo AM; Amici A; Penichet ML; Aurisicchio L; Iezzi M; Musiani P; Nanni P; Lollini PL
    Hum Gene Ther; 2009 May; 20(5):453-64. PubMed ID: 19215191
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice.
    Quaglino E; Mastini C; Iezzi M; Forni G; Musiani P; Klapper LN; Hardy B; Cavallo F
    Vaccine; 2005 May; 23(25):3280-7. PubMed ID: 15837233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming.
    Romieu-Mourez R; François M; Abate A; Boivin MN; Birman E; Bailey D; Bramson JL; Forner K; Young YK; Medin JA; Galipeau J
    Cancer Res; 2010 Oct; 70(20):7742-7. PubMed ID: 20924101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine.
    Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD
    Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
    Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
    Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy.
    Rolla S; Ria F; Occhipinti S; Di Sante G; Iezzi M; Spadaro M; Nicolò C; Ambrosino E; Merighi IF; Musiani P; Forni G; Cavallo F
    J Immunol; 2010 Jun; 184(11):6124-32. PubMed ID: 20435927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunological prevention of a multigene cancer syndrome.
    Croci S; Nicoletti G; Landuzzi L; De Giovanni C; Astolfi A; Marini C; Di Carlo E; Musiani P; Forni G; Nanni P; Lollini PL
    Cancer Res; 2004 Nov; 64(22):8428-34. PubMed ID: 15548714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
    Amici A; Smorlesi A; Noce G; Santoni G; Cappelletti P; Capparuccia L; Coppari R; Lucciarini R; Petrelli C; Provinciali M
    Gene Ther; 2000 Apr; 7(8):703-6. PubMed ID: 10800094
    [TBL] [Abstract][Full Text] [Related]  

  • 50. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice.
    Cappello P; Triebel F; Iezzi M; Caorsi C; Quaglino E; Lollini PL; Amici A; Di Carlo E; Musiani P; Giovarelli M; Forni G
    Cancer Res; 2003 May; 63(10):2518-25. PubMed ID: 12750275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
    Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
    Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance.
    Ambrosino E; Spadaro M; Iezzi M; Curcio C; Forni G; Musiani P; Wei WZ; Cavallo F
    Cancer Res; 2006 Aug; 66(15):7734-40. PubMed ID: 16885376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
    Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Dörken B; Pezzutto A; Westermann J
    Cancer Gene Ther; 2012 Jan; 19(1):69-76. PubMed ID: 21997231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In silico modeling and in vivo efficacy of cancer-preventive vaccinations.
    Palladini A; Nicoletti G; Pappalardo F; Murgo A; Grosso V; Stivani V; Ianzano ML; Antognoli A; Croci S; Landuzzi L; De Giovanni C; Nanni P; Motta S; Lollini PL
    Cancer Res; 2010 Oct; 70(20):7755-63. PubMed ID: 20924100
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
    Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
    Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice.
    Curcio C; Khan AS; Amici A; Spadaro M; Quaglino E; Cavallo F; Forni G; Draghia-Akli R
    Cancer Gene Ther; 2008 Feb; 15(2):108-14. PubMed ID: 17992201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
    Singh R; Paterson Y
    Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.
    Lo Iacono M; Cavallo F; Quaglino E; Rolla S; Iezzi M; Pupa SM; De Giovanni C; Lollini PL; Musiani P; Forni G; Calogero RA
    Int J Immunopathol Pharmacol; 2005; 18(2):351-63. PubMed ID: 15888257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
    Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.